SANUWAVE Health, Inc.
No SEC Form 4 filings for $SNWV in the last 30 days.
SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-991snwvpressreleasex806.htm EX-99.1 Document Exhibit 99.1 Sanuwave Announces Q2 FY2026 Financial Results Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income w
Sanuwave Health (NASDAQ:SNWV) said it expects Q2 2026 revenue of $9.6 million to $9.8 million, above prior guidance of $8.5 million to $9.5 million. The company noted Q2 revenue is about 3% to 5% lower year over year from $10.1 million. It cited pressured capital sales but record consumable applicator momentum and offered trade-in and support programs. Shares were down 4.44% to $6.36.
Sanuwave Health (SNWV) issued a preliminary Q2 2026 revenue outlook of $9.6 to $9.8 million, down about 3% to 5% from $10.1 million in Q2 2025. The estimate is above the company’s revised June 16 guidance of $8.5 to $9.5 million, which it lowered due to market disruption impacting Ultramist capital equipment sales.
Over the past 7 days, alphai's AI scored 1 news story mentioning SNWV (SANUWAVE Health, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent SNWV coverage spans earnings, financial news and market movers.
Guidance withdrawal and reimbursement-driven uncertainty increase near-term earnings risk, while applicator demand signals partially offset system-sales weakness.
Guidance raise plus consumables strength is a near-term positive, but capital sales pressure and the stock down on the day suggest investors are weighing durability.
Preliminary Q2 revenue coming in above lowered guidance reduces near-term downside risk from the earlier market disruption to Ultramist capital equipment sales.
Preliminary Q2 revenue beat versus revised guidance suggests improving near-term demand and/or consumables momentum, potentially lifting sentiment ahead of the August earnings report.
This is a preliminary results disclosure via 8-K, but the scraped text does not include the actual financial figures or guidance.
alphai scores every news story that mentions SNWV with an AI model for sentiment and relevance, and aggregates insider trades from SANUWAVE Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-991snwvpressreleasex806.htm EX-99.1 Document Exhibit 99.1 Sanuwave Announces Q2 FY2026 Financial Results Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income w
6 min readSanuwave Health (NASDAQ:SNWV) said it expects Q2 2026 revenue of $9.6 million to $9.8 million, above prior guidance of $8.5 million to $9.5 million. The company noted Q2 revenue is about 3% to 5% lower year over year from $10.1 million. It cited pressured capital sales but record consumable applicator momentum and offered trade-in and support programs. Shares were down 4.44% to $6.36.
4 min readSanuwave Health (SNWV) issued a preliminary Q2 2026 revenue outlook of $9.6 to $9.8 million, down about 3% to 5% from $10.1 million in Q2 2025. The estimate is above the company’s revised June 16 guidance of $8.5 to $9.5 million, which it lowered due to market disruption impacting Ultramist capital equipment sales.
2 min readSanuwave Health (NASDAQ: SNWV) reported preliminary, unaudited Q2 2026 revenue of $9.6 million to $9.8 million, above its revised guidance high end of $9.5 million. The company said this is down about 3% to 5% from $10.1 million in Q2 2025. Results are subject to adjustment after quarter-end close.
2 min readSANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. snwv-20260713 FALSE 0001417663 0001417663 2026-07-13 2026-07-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported)
2 min readBiotech stocks rose on company-specific catalysts. Virax Biolabs (VRAX) jumped over 100% after signing an exclusive multi-country supply agreement with Fosun Diagnostics for ImmuneSelect. Forte Biosciences (FBRX) gained about 78% on positive Phase 1b vitiligo data for FB102. First Tracks (TRAX) rose ~56% without news. TransCode (RNAZ) and Connect Biopharma (CNTB) also climbed; Sanuwave (SNWV) fell guidance and expects Q2 revenue of $8.5m to $9.5m.
6 min readSANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. snwv-20260611 FALSE 0001417663 0001417663 2026-06-11 2026-06-11 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported
2 min readEDEN PRAIRIE, Minn., May 28, 2025 ( GLOBE NEWSWIRE ) -- Sanuwave Health, Inc. SNWV, a leading provider of next-generation, non-invasive wound care solutions, today announced, as part of the 2025 Russell indexes reconstitution, the Company's inclusion in the Russell 2000® Index.
2 min readEDEN PRAIRIE, Minn., May 28, 2025 ( GLOBE NEWSWIRE ) -- Sanuwave Health, Inc. ( NASDAQ: SNWV ) , a leading provider of next-generation, non-invasive wound care solutions, today announced, as part of the 2025 Russell indexes reconstitution, the Company's inclusion in the Russell 2000® Index.
2 min readEDEN PRAIRIE, Minn., May 28, 2025 ( GLOBE NEWSWIRE ) -- Sanuwave Health, Inc. ( the "Company" or "Sanuwave" ) SNWV, a leading provider of next-generation FDA-approved wound care products, is pleased to announce the addition of Greg Bazar to its Board of Directors.
2 min read
